GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck KGaA (XTER:MRK) » Definitions » ROE %

Merck KGaA (XTER:MRK) ROE % : 11.38% (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Merck KGaA ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Merck KGaA's annualized net income for the quarter that ended in Sep. 2024 was €3,236 Mil. Merck KGaA's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was €28,436 Mil. Therefore, Merck KGaA's annualized ROE % for the quarter that ended in Sep. 2024 was 11.38%.

The historical rank and industry rank for Merck KGaA's ROE % or its related term are showing as below:

XTER:MRK' s ROE % Range Over the Past 10 Years
Min: 7.53   Med: 11.8   Max: 21.63
Current: 9.64

During the past 13 years, Merck KGaA's highest ROE % was 21.63%. The lowest was 7.53%. And the median was 11.80%.

XTER:MRK's ROE % is ranked better than
66.36% of 966 companies
in the Drug Manufacturers industry
Industry Median: 4.485 vs XTER:MRK: 9.64

Merck KGaA ROE % Historical Data

The historical data trend for Merck KGaA's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck KGaA ROE % Chart

Merck KGaA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.53 11.42 15.96 14.07 10.74

Merck KGaA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.76 8.54 10.15 8.59 11.38

Competitive Comparison of Merck KGaA's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck KGaA's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's ROE % distribution charts can be found below:

* The bar in red indicates where Merck KGaA's ROE % falls into.



Merck KGaA ROE % Calculation

Merck KGaA's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=2824/( (25927+26680)/ 2 )
=2824/26303.5
=10.74 %

Merck KGaA's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=3236/( (28549+28323)/ 2 )
=3236/28436
=11.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Merck KGaA  (XTER:MRK) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=3236/28436
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(3236 / 21064)*(21064 / 50008.5)*(50008.5 / 28436)
=Net Margin %*Asset Turnover*Equity Multiplier
=15.36 %*0.4212*1.7586
=ROA %*Equity Multiplier
=6.47 %*1.7586
=11.38 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=3236/28436
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (3236 / 4172) * (4172 / 4396) * (4396 / 21064) * (21064 / 50008.5) * (50008.5 / 28436)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7756 * 0.949 * 20.87 % * 0.4212 * 1.7586
=11.38 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Merck KGaA ROE % Related Terms

Thank you for viewing the detailed overview of Merck KGaA's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck KGaA Business Description

Address
Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
Executives
Peter Guenter Member of the Executive Board
Dr. Matthias Heinzel Member of the Executive Board
Belén Garijo Lopez Chair of the Executive Board
Dr. Marcus Kuhnert Board of Directors